Loading...
•
Jun 30, 2022
Caribou Biosciences Q2 2022 Earnings Report
Reported financial results for the second quarter of 2022 and provided a business update.
Key Takeaways
Caribou Biosciences reported financial results for the second quarter of 2022, highlighting a strong financial position with $366.1 million in cash, cash equivalents, and marketable securities. The company made significant progress in advancing its pipeline of genome-edited allogeneic CAR-T and CAR-NK cell therapies, including encouraging initial clinical data from the Phase 1 ANTLER trial for CB-010.
Reported 6-month complete response (CR) in 3 of 6 patients across cohort 1 of the CB-010 ANTLER Phase 1 clinical trial.
Additional cohort 1 data expected by YE 2022; enrolling patients in cohort 2 of ANTLER trial.
CB-011 IND submission planned for Q4 2022 in patients with r/r MM.
CB-012 on track for 2023 IND submission in patients with r/r AML.
Caribou Biosciences
Caribou Biosciences
Caribou Biosciences Revenue by Segment
Revenue by Segment
Licensing and collaboration Revenue
CapyFin.com Forward Guidance
Caribou Biosciences anticipates several milestones for 2022 and beyond, including sharing additional data from cohort 1 of the ANTLER Phase 1 trial for CB-010 by YE 2022, submitting an IND application for CB-011 in Q4 2022, announcing target selection for CB-020 in Q4 2022, and submitting an IND application for CB-012 in 2023.
Positive Outlook
- Plans to share additional data from cohort 1 of the ongoing ANTLER Phase 1 trial for CB-010 by YE 2022.
- Expects to submit an IND application for CB-011 in Q4 2022.
- Expects to announce target selection for CB-020 in Q4 2022.
- Expects to disclose armoring strategies under development for its CAR-NK cell platform in Q4 2022.
- Expects to submit an IND application for CB-012 in 2023.